This is a prospective observational phase IV study of a novel, replication-deficient smallpox vaccine that has been recently been approved by FDA. The purpose of this study is to determine if there are any abnormalities detected by electrocardiographic testing and/or blood tests within 35 days of receiving the second dose of smallpox vaccine either alone or co-administered with other vaccines that may/may not be suggestive of myopericarditis.

开始日期2029-03-01

申办/合作机构

Womack Army Medical Center

[+1]

NCT07199569

/ Active, not recruiting临床2期

A Randomized, Double-blind, Phase 2b Comparability Trial in Adults 18 to 49 Years of Age to Assess Immunogenicity, Safety, and Reactogenicity of the MVA-BN Vaccine Manufactured in Different Production Cells

Randomized, double-blind, phase 2b trial to assess comparability in immunogenicity, safety, and reactogenicity of MVA-BN vaccine manufactured in primary chicken embryo fibroblast (CEF) cells and the CCX.E10 quail cell line in adults

开始日期2025-10-27

申办/合作机构

Bavarian Nordic A/S

[+1]

NCT06844487

/ Recruiting临床3期IIT

Phase 3, Randomised Maternal and Infant (From 4 to 24 Months of Age) Safety and Immunogenicity Trial of MVA-BN® Vaccine in the Democratic Republic of the Congo

This Phase 3 double-blinded, randomized study aims to evaluate the safety and immunogenicity of the two-dose MVA-BN mpox vaccine regimen, administered subcutaneously, in infants and children aged 4 to 24 months in the Democratic Republic of the Congo (DRC), a population at high risk of mpox infection and complications. The study will compare the safety and immunogenicity of a full-dose regimen versus a half-dose regimen in this population. A hierarchical testing strategy will be applied as follows: first, non-inferiority of the full-dose regimen in infants/children (4-24 months old) will be evaluated against the full-dose regimen in adults from the POX-MVA-045 study. If non-inferiority is demonstrated, the immunogenicity of the half dose in infants/children (4-24 months old) will subsequently be tested for non-inferiority vs the full dose in adult. The trial will be conducted in Boende, Tshuapa Province, DRC.
The trial plans to enroll 344 male and female infants/children, who will be randomized to receive two doses of the MVA-BN vaccine administered 28 days apart. Participants in Child Group 1 (N=172) will receive the standard vaccine dose (0.5 mL), while those in Child Group 2 (N=172) will receive half the standard dose (0.25 mL), with both groups following the same dosing schedule.
This study builds on positive safety and immunogenicity data from prior trials that support the use of the standard dose regimen in younger children. However, considering the developmental differences in the immune systems of infants and young children/adolescents, it aims to evaluate whether a half-dose regimen can provide similar immunogenicity while potentially reducing reactogenicity. The findings will offer valuable insights into the optimal dosing strategy for this age group, balancing safety and immunogenicity to inform future vaccination recommendations.

开始日期2025-05-29

申办/合作机构

University of Antwerp

[+5]

100 项与天花和猴痘活疫苗(Bavarian Nordic A/S) 相关的临床结果

登录后查看更多信息

100 项与天花和猴痘活疫苗(Bavarian Nordic A/S) 相关的转化医学

登录后查看更多信息

100 项与天花和猴痘活疫苗(Bavarian Nordic A/S) 相关的专利（医药）

登录后查看更多信息

163

项与天花和猴痘活疫苗(Bavarian Nordic A/S) 相关的文献（医药）

2026-03-01·REVIEWS IN MEDICAL VIROLOGY

From Surge to Stability: Navigating MPOX Epidemics Across the Globe With Genomic Insights, Paving the Way for Effective Management Plan

Review

作者: Shahzad, Muhammad ; Malik, Tooba ; Akhtar, Tasleem

ABSTRACT:

MPOX has been declared endemic in Central Africa by WHO in 2017. More recently (2018–2021), MPOX cases have been reported in various regions (endemic as well as non‐endemic) all over the world. The sudden, unexpected and simultaneously emerging cases at geographically disparate areas indicate the probable undetected transmission pattern of the disease. The double stranded DNA virus has evolved over the time into multiple sub‐lineages. Clade I MPXV variant is considered to be more virulent as compared to clade II variety. Mutations in certain sub‐lineages may alter transmission routes, potentially shifting from direct contact to airborne transmission. The clinical presentation involves an incubation phase of 7–9 days, during this phase extensive viral dissemination occurs into the neighbouring cells causing systemic inflammation. The viral prodrome comprising of fever, malaise and myalgias may or may not precede the cutaneous eruptions that evolve over a period of 1–2 weeks, followed by desquamation and scabbing. Treatments include antiviral agents such as tecovirimat, bocindofovir and cidofovir in addition to standard supportive therapy for severe cases or immunocompromised patients. Vaccines such as ACAM2000, JYNNEOS and LC16m8 are available, although they are linked with some risks such as myopericarditis in certain patients. Ongoing global spread and virus mutations highlight the urgent need to accelerate research focused on early MPOX detection, novel treatment options and prevention in order to properly handle potential long‐term challenges such as drug‐resistant strains and future outbreaks. Prioritising the development of targeted, efficient, and less resistance‐prone anti‐MPOX medicines and rapid response systems for effective MPOX management.

2026-02-02·Open Forum Infectious Diseases

Persistent Immunity From Historic Smallpox Vaccination and Its Limited Cross-Neutralization of Monkeypox Virus: A Population-based Serological Study in Taiwan

Article

作者: Fang, Wen-Hui ; Chen, Yen-Chen ; Chen, An-Yu ; Huang, Chih-Heng ; Lin, Le-Tien ; Hung, Yi-Jen

Abstract:

Background:

Understanding the extent of cross-protection conferred by the historic smallpox vaccination and the immunogenicity of Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) after the 2022 global mpox outbreak is essential to inform current prevention strategies. In this study, we assessed the seropositivity and neutralizing capacities of the vaccinia virus (VACV)- and monkeypox virus (MPXV)-specific antibodies in 260 Taiwanese individuals.

Methods:

We analyzed serum samples from 260 individuals in Taiwan, stratified by their birth year, before or after 1979, the year of smallpox vaccination cessation. ELISA and plaque reduction neutralization tests were conducted to assess VACV- and MPXV-specific antibody responses. Furthermore, we evaluated an additional cohort of MVA-BN vaccines (n = 9) before and after vaccination.

Results:

Over 80% of individuals born before 1979 retained VACV-reactive antibodies, with 84% of this seropositive subgroup exhibiting neutralizing activity. We detected cross-reactive MPXV antibodies in 69% of individuals who were VACV-seropositive; however, only 65% had MPXV-neutralizing capacity, with titers significantly lower than those against VACV. MVA-BN vaccination enhanced VACV and MPXV antibody levels; however, MPXV-neutralizing titers remained low, particularly in individuals without prior smallpox immunization.

Conclusions:

Historical smallpox vaccination induces long-lasting humoral immunity, and a correlation between VACV and MPXV antibody levels further suggests that it provides some degree of cross-protection against MPXV infection. MVA-BN boosted orthopoxvirus immunity; however, it may be limited in MPXV neutralization in vaccine-naïve populations. These findings offer useful insights for future mpox vaccination strategies and public health planning in regions with varying smallpox vaccination histories.

2026-02-01·Infectious disorders drug targets

A Mini Review on Monkey-Pox: Outbreak, Challenges, and Management Strategies

Article

作者: Ushir, Yogesh V ; Singh, Sudarshan ; Thorat, Dipak S. ; Nagime, Pooja V

Monkeypox (Mpox) has become a significant global health concern, particularly since 2022. It has spread rapidly to numerous locations, and we urgently need to learn more about it. This overview discusses what Mpox is, how it spreads, its effects on people, and the medications that can be used to assist. Between January 2022 and March 2025, approximately 129,523 people were infected with Mpox in 120 countries. This demonstrates that HPV has progressed from being passed down from animals to being transmitted between people, including through intimate touch, as in some sexual interactions. Scientists discovered significant alterations in the virus that could help it adapt to people. Currently, we do not have many therapy alternatives. However, certain medications, such as tecovirimat and cidofovir, as well as specific vaccines (such as MVA-BN), can aid in recovery. When administered promptly after exposure, the vaccine is extremely effective in protecting people. This review emphasizes the importance of detecting Mpox early, monitoring the virus's evolution, and ensuring that people, particularly those who are more susceptible to illness, are immunized. A One Health strategy, which encompasses the care of humans, animals, and the environment in a unified approach, is crucial to preventing future outbreaks. To keep everyone safe, we must prepare for and strengthen our response to Mpox.

409

项与天花和猴痘活疫苗(Bavarian Nordic A/S) 相关的新闻（医药）

2026-04-15

·让ICU不再神秘

从应急到常态化，猴痘疫情的新进展

非洲大陆公共卫生紧急防控级别取消猴痘相关警报，是流行病学和公共卫生领域的一个重要里程碑，也具备相应政策意义。但大家千万别觉得，取消紧急状态就等于猴痘问题彻底解决了。恰恰相反，这是一个关键契机：我们要巩固疫情应急阶段取得的科研成果，补上目前还存在的科研短板、完善相关配套工作。与此同时，抗病毒药物研发、快速诊断技术优化、疫苗预防接种方案制定、真实临床疗效研究取证，还有保障非洲地区平等参与主导科研工作，这些事都得接着扎实推进。《柳叶刀・传染病》期刊近期刊发了多项新研究，围绕疫苗的免疫效果与安全性、临床发病特点、检测诊断性能展开分析，让我们对猴痘的传播规律、防控手段效果，有了更清晰全面的认知。一、疫苗相关重要发现刚果（金）的研究数据显示：改良安卡拉痘苗疫苗（MVA-BN，巴伐利亚北欧款），给医护人员打完标准两针基础疫苗后，保护免疫记忆能维持长达 5 年。再打一针加强针，身体会快速产生强效免疫反应：接种 14 天后，中和抗体浓度能涨近 90 倍；打完一年半左右，抗体水平依旧是接种前的 6 倍。这也贴合世卫组织最新建议 —— 在非洲猴痘常年流行的地区，常态化开展疫苗接种是可行的。简单说：就算体内短期抗体变少了，长久的免疫保护记忆还在，长期接种疫苗的策略靠得住。另一项针对 1600 名刚果（金）医护人员的研究证实：这款疫苗加强针安全性很好，没出现严重不良反应，液体剂型和冻干剂型的安全表现也没啥差别。这类数据，能大幅提升疫区民众对接种疫苗的信任感。不过也要注意差异：瑞典等欧洲国家研究发现，疫苗防护效果大概 6 个月后会慢慢减弱；乌干达当初疫苗不够用时，推行过单针接种来快速控疫情，虽然能压住暴发，但单针疫苗的长效保护效果，目前还没法确定。这些差异都说明：必须针对非洲本土情况持续做研究，才能制定出贴合当地实际的疫苗接种政策。二、疫区接种疫苗，核心意义要理清说到底，疫苗是用来提前防病的工具。现在越来越多证据表明：猴痘高发疫区，可以推行预防性接种，有望在特定人群里形成群体免疫。虽说落地执行、资金投入、伦理考量还有不少难题，但现在有了充足数据，我们可以长远规划：从过去疫情来了才临时接种，变成常态化提前预防。这也能推动非洲本土自研自产猴痘疫苗，让疫苗能公平分配、惠及更多人。三、治疗药物研发进展慢，仍需攻坚目前，还没有正式获批上市的猴痘专用治疗药物。哪怕相关医疗防护技术一直在进步，特效药的研发进度还是明显滞后。好在非洲正在开展猴痘药物临床试验，很快就能拿出关键依据，明确抗病毒药在非洲疫区的实际效果、敲定最优临床治疗方案。另外，业内也在研究减量接种、单针接种等办法，想缓解全球疫苗紧缺问题，提高接种覆盖率。这些研究，能把实验室里的免疫数据，变成真实临床场景的防护效果，以后再出现疫情反弹，也能科学节约疫苗、合理分配剂量。四、快速检测仍是最大短板乌干达、刚果（金）多地实测猴痘快速抗原检测试剂：野外基层能用、操作方便，但整体准确率达不到世卫组织设定的标准，刚果（金）地区准确率偏低。就算乌干达检测效果稍好，也会受病毒载量、发病时长、患者年龄影响 —— 只靠皮肤病灶采样做抗原快检，现在还有明显局限。快速检测适合基层分散筛查，但在多数疫区，还是替代不了精准的 PCR 核酸检测。好消息是，实验室精准检测技术在进步：卢旺达研发的猴痘 IgG 抗体筛查试剂盒，能清晰区分感染者、接种疫苗者、从没接触过病毒的普通人，抽血检测和干血斑采样检测结果也高度吻合。这类技术能大范围开展人群抗体筛查、评估整体免疫水平，给常态化疫苗接种监测提供支撑。不过目前还有个关键问题没解决：我们还没明确 “体内抗体达到多少浓度，就能稳稳防住得病”。没有这个标准，单凭抗体数值定防控政策，只能靠推测，不够精准。五、发病人群、临床症状出现新变化刚果（金）一项研究统计了 494 例猴痘确诊病例，发现一个明显变化：现在得病的大多是儿童和青少年。而且地域差异很大：刚果（金）儿童病例变多、一家人扎堆感染常见，还容易出现口腔黏膜病变；乌干达则主要是年轻人得病，几乎没有儿童病例。再加上不少患者症状不典型，原来的病例判定标准已经不够用了，必须针对性出台面向青少年、儿童的全新防控策略。另外，有些患者身上没长皮肤疱疹，但咽喉采样能查出病毒，这也刷新了我们对传播途径、采样检测方式的认知。六、三大核心经验总结非洲猴痘疫区完全能开展高质量科研：哪怕当地有战乱、基础设施薄弱，现场做疫苗试验、检测评估、病例随访，照样能拿出扎实、能指导政策的硬核数据。疫区不只是单纯提供样本数据，更是能产出原创科研成果的地方。防疫准备要常态化，不能临时抱佛脚。如今全球、非洲大陆的紧急警报都取消了，但这不是放松躺平的信号，而是要长期保持警惕。诊断短板没补齐、特效药没落地、发病人群还在变，猴痘疫情始终存在变数。必须把疫苗接种、实验室检测能力、灵活监测机制，融入日常医疗体系，才能防止疫情反复暴发。必须强化非洲本土的科研主导权：很多非洲相关的重磅研究，第一作者、核心资深研究者都不是非洲本土人员，科研不公平的问题一直存在。统一研究标准、简化伦理审批和监管流程、开展应急演练、保障专属的快速科研经费，都至关重要。让非洲科研人员平等署名、能自主设计试验、分析数据、发表成果，不只是面子问题，更是保障非洲本土医疗安全、掌握长期科研主动权的根本。七、未来五大科研重点猴痘防控从应急处置转入长期管理后，科研方向也要跟着调整，核心抓五件事：①加快针对非洲疫区人群的临床试验；②优化快速检测试剂，达标世卫组织精准要求；③明确能真正防病的抗体标准；④完善预防性疫苗接种整套方案；⑤提升非洲本土科研主导能力。疫情期间攒下的科研成果，要落地成长期稳定的医疗体系、公平的国际合作、持续的资金投入，杜绝疫情卷土重来。如今猴痘已经在非洲扎根成为常见病，必须把长效疫苗接种、精准检测、灵活监测、非洲自主科研，融入日常医疗服务，才能实现精准防控、自主可控，守住长久的公共卫生安全。 https://doi.org/10.1016/S1473-3099(26)00121-0

2026-03-27

·BioSpace

Bavarian Nordic Submits Data to EMA to Extend Mpox and Smallpox Vaccine Approval to Children Aged 2-11 Years

Submission based on topline data from clinical study, demonstrating a comparable safety pro a non-inferior immune response for MVA-BN in children aged 2-11 years compared to adults. COPENHAGEN, Denmark, March 27, 2026 – Bavarian Nordic A/S (OMX: BAVA) has submitted clinical data to the European Medicines Agency (EMA) to support the extension of the MVA-BN ® mpox and smallpox vaccine indication to include children aged 2 to 11 years. The submission is based on positive topline results from a Phase 2 clinical study ( NCT06549530 ) in 227 children aged 2-11 years and 224 adults demonstrating non-inferiority of the immune responses as well as a similar safety profile, between both age groups after vaccination with two standard doses of the MVA-BN vaccine. The study was co-funded by the Coalition for Epidemic Preparedness Innovations (CEPI) and was conducted at sites in the Democratic Republic of Congo (DRC) and Uganda. Both countries reported cases of mpox in adults and children during the recent outbreak across Africa and the world. Following review of the data by EMA, the Marketing Authorisation for MVA-BN could be extended to include use of the vaccine for individuals from 2 years of age later in 2026. “The submission of data for children aged 2-11 years to EMA marks another leap in the advancement of our MVA‑BN vaccine to protect populations broadly against mpox and smallpox,” said Paul Chaplin, President and Chief Executive Officer of Bavarian Nordic. “While the risk of mpox in Africa is now more moderate, children remain disproportionally affected by the disease, highlighting the importance to broaden the access to vaccines and therapies for this vulnerable population. Our collaboration with CEPI and local partners in Africa has been instrumental in generating the data to support this submission, and together we continue our endeavors to ensure access to the vaccine for other vulnerable populations.” Dr Kristine Rose, Mpox Disease Programme Lead at CEPI , said: “ Children have been significantly impacted during recent global outbreaks of mpox, with many facing a higher risk of severe disease compared to adults - especially when other health challenges, such as malnutrition, malaria or HIV, are present. This has led to ongoing suffering in the younger populations and continued transmission of the virus, underscoring the need to expand access to vaccines specifically for this age group. Bavarian Nordic’s submission to a WHO listed Authority like the EMA is an important step towards protecting children around the world as, following potential expansion of the vaccine to younger demographics, other regulators could follow suit. ” Professor Hypolite Muhindo Mavoko, University of Kinshasa, principal investigator of the study , said: “In the Democratic Republic of the Congo, children aged 2 to under 12 years represent nearly one-third of the population and are disproportionately affected by mpox complications. Because children interact closely with one another and within households, they can also contribute to ongoing transmission. Expanding vaccine access to this age group is therefore an important step to better protect vulnerable populations and strengthen outbreak control, while reducing the health and economic burden associated with mpox.” About the mpox/smallpox vaccine MVA-BN or Modified Vaccinia Ankara-Bavarian Nordic is the only non-replicating mpox vaccine approved in the U.S., Switzerland, Singapore, Mexico (marketed as JYNNEOS ® ), Canada (marketed as IMVAMUNE ® ), the EU/EAA and United Kingdom (marketed as IMVANEX ® ). Originally developed as a smallpox vaccine in collaboration with the U.S. government to ensure the supply of a smallpox vaccine for the entire population, including immunocompromised individuals who are not recommended vaccination with traditional replicating smallpox vaccines, MVA-BN has been indicated for use in the general population (from 12 years old) in individuals considered at risk for smallpox or mpox infection. About Bavarian Nordic Bavarian Nordic is a global vaccine company with a mission to improve health and save lives through innovative vaccines. We are a preferred supplier of mpox and smallpox vaccines to governments to enhance public health preparedness and have a leading portfolio of travel vaccines. For more information, visit Forward-looking statements This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law. Contact investors: Europe: Disa Tuominen, IR Manager, detu@bavarian-nordic.com US: Graham Morrell, Gilmartin Group, graham@gilmartinir.com , Tel: +1 781 686 9600 Contact media: Nicole Seroff, Vice President Corporate Communications, nise@bavarian-nordic.com , Tel: +45 53 88 06 03 Attachment Bavarian Nordic Submits Data to EMA to Extend Mpox and Smallpox Vaccine Approval to Children Aged 2-11 Years

疫苗临床结果临床2期上市批准

2026-03-14

·生物制品圈

反向疫苗学3.0：AI正在改写疫苗研发的底层规则

摘要：2000年，反向疫苗学第一次推翻了疫苗研发的传统逻辑。16年后，2.0版本完成了第二次迭代。如今AI深度入局的3.0时代，直接把抗原发现的周期从数年压缩到了数天。这篇内容，我会跟大家聊透这套技术的三次迭代，实战成果，还有它藏在疫苗之外的可能性。反向疫苗学的前两次迭代，改写了疫苗研发的规则反向疫苗学的概念，2000年首次被提出。它彻底换掉了沿用多年的病原体灭活、减毒的经验式研发思路。直接从病原体的基因组序列出发，筛选能诱导保护的抗原。第一个落地的是B群脑膜炎奈瑟菌疫苗，整个研发周期只用了5年。 2016年，反向疫苗学2.0正式出现。支撑它的，是人类免疫学和结构生物学的跨越式进步。研发人员从康复者或感染者体内分离人源单克隆抗体，定位保护性抗原，解析抗原-抗体复合物的结构，完成免疫原的理性设计。首款获批的RSV疫苗，就是这套技术的核心成果。新冠疫情期间，这个方法也快速完成了刺突蛋白上保护性表位的定位。给后续广谱疫苗和抗体的研发，抢出了关键的时间窗口。AI入局的3.0，把抗原发现压缩到了5天图1 反向疫苗学3.0核心技术路线示意图反向疫苗学3.0的核心，是把前两代的技术积累，和AI驱动的结构生物学做了深度融合。它第一次成功落地，是在猴痘病毒（MPXV）的抗原发现上，结果直接刷新了整个领域的认知。传统的正痘病毒疫苗，依赖活病毒减毒的老方法。这套方法消灭了天花，但对猴痘的效果有限，还存在不少使用限制。传统实验室筛选，在35个以上的猴痘抗原里，只找到了7个中和抗体靶点。这些靶点单价使用时，只能中和单一形态的病毒体。想要实现完整保护，必须多抗原联用。1976年后出生的人群对正痘病毒普遍没有免疫力，也让猴痘的全球传播风险持续走高。用3.0的技术路线，研发人员先从猴痘感染者、MVA-BN疫苗接种者体内，做抗原非依赖的记忆B细胞分离。筛选能同时中和两种病毒形态的抗体，最终找到了12株能交叉中和不同猴痘分支的单抗。这类能跨毒株、跨病毒形态实现广谱中和的单抗，之前从来没有被报道过。研发人员把抗体和猴痘表面抗原的序列，输入AlphaFold 3做预测建模，只用了5天，就拿到了两个高置信度的结果。这次筛选，锁定了之前完全未知的中和靶点OPG153。后续的冷冻电镜实验，直接验证了AI的预测结果。体内免疫实验显示，单价OPG153加佐剂诱导的中和滴度，和减毒活疫苗、多价mRNA疫苗水平相当。坦白讲，这个结果最打动我的，不只是速度上的飞跃。它跳出了传统方法的筛选边界，找到了之前完全没被发现的优质抗原，这才是最有冲击力的地方。AI能做的，远不止快速找抗原传统的抗原、抗体优化，大多只停留在提升表达量的层面。AlphaFold、RoseTTAFold这类工具出现后，AI能同时优化分子的溶解度、热稳定性、蛋白酶抗性，还能精准调整抗原的表位呈现，诱导更广谱的免疫保护。经过AI优化的新冠抗原，多价展示后能稳定提升抗体的效价和广谱性。嵌合了不同沙贝病毒受体结合域的纳米颗粒，在小鼠体内诱导的抗体，能中和之前从未接触过的蝙蝠、穿山甲来源的沙贝病毒。抗体的体外优化也有了突破性进展。生成式设计框架，能把对奥密克戎失效的临床抗体，恢复中和活性，还能同时覆盖多个变异株。病毒语言模型，能提前预测病毒的免疫逃逸突变，优先筛选能扛住进化的抗体。某种程度上，这个领域已经走到了一个关键节点。我们已经能完全从头设计抗原和抗体分子，不需要天然序列做模板，直接生成符合预期功能的优化分子。它的边界，从来不止于疫苗其实这套技术的想象空间，早就跳出了传染病疫苗的范畴。肿瘤疫苗研发里，几天内完成新抗原的筛选和验证，能给个体化肿瘤治疗带来质的飞跃。自身免疫病领域，我们能通过设计特定的免疫原，引导免疫系统走向更耐受的状态。老药新用的筛选也能被彻底提速。我们能在电脑上，快速完成已上市药物和任意靶点抗原的结合筛选，大大降低研发成本和时间周期。当然，现在的3.0还远没到完美的地步。猴痘抗原的发现实验里，AlphaFold 3的高置信度预测成功率只有25%，8个靶向同一抗原的单抗里，只有2个拿到了准确结果。 AI工具的效果，极度依赖高质量的大数据积累。蛋白结构领域有PDB库几十年、超20万条结构的积累，但系统疫苗学、固有免疫、佐剂研发这些领域，还没有足够的数据集，AI能发挥的作用还很有限。说起来，技术的迭代从来都不是一步到位的。但这一次的突破，已经给我们指了一条足够清晰的路。参考来源：https://doi.org/10.1038/s41579-026-01286-y 识别微信二维码，添加生物制品圈小编，符合条件者即可加入生物制品微信群！请注明：姓名+研究方向！版权声明本公众号所有转载文章系出于传递更多信息之目的，且明确注明来源和作者，不希望被转载的媒体或个人可与我们联系(cbplib@163.com)，我们将立即进行删除处理。所有文章仅代表作者观不本站。

疫苗信使RNA

100 项与天花和猴痘活疫苗(Bavarian Nordic A/S) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	天花和猴痘活疫苗(Bavarian Nordic A/S)	J07BX	DB15483

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
猴痘	欧盟	Bavarian Nordic A/S	2013-07-31
猴痘	冰岛	Bavarian Nordic A/S	2013-07-31
猴痘	列支敦士登	Bavarian Nordic A/S	2013-07-31
猴痘	挪威	Bavarian Nordic A/S	2013-07-31
天花	欧盟	Bavarian Nordic A/S	2013-07-31
天花	冰岛	Bavarian Nordic A/S	2013-07-31
天花	列支敦士登	Bavarian Nordic A/S	2013-07-31
天花	挪威	Bavarian Nordic A/S	2013-07-31
牛痘病毒感染	欧盟	Bavarian Nordic A/S	2013-07-31
牛痘病毒感染	冰岛	Bavarian Nordic A/S	2013-07-31
牛痘病毒感染	列支敦士登	Bavarian Nordic A/S	2013-07-31
牛痘病毒感染	挪威	Bavarian Nordic A/S	2013-07-31

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05740982 (CTgov)	临床2期	猴痘	450	MVA-BN (Modified Vaccinia Ankara-Bavarian Nordic) (Adolescents)	鹽蓋積鑰蓋憲網窪鏇餘(餘齋簾壓積醖製範餘觸) = 糧鑰窪衊願鏇艱醖積觸構構繭築醖齋積獵築鏇 (淵窪齋製範選鑰願積築, 窪艱鑰壓選糧顧憲鑰鹹 ~ 淵鬱廠構膚淵鬱廠鬱鏇) 更多	-	2026-03-27
				MVA-BN (Modified Vaccinia Ankara-Bavarian Nordic) (Adults (Stage 2))	鹽蓋積鑰蓋憲網窪鏇餘(餘齋簾壓積醖製範餘觸) = 淵糧築簾餘襯膚餘築網構構繭築醖齋積獵築鏇 (淵窪齋製範選鑰願積築, 鏇窪糧齋顧遞襯範夢遞 ~ 鬱鏇鏇選廠憲糧選觸獵) 更多
NCT05734508 (CTgov)	临床4期	猴痘	500	MVA-BN Mpox Vaccine	鹹積衊積範築觸醖醖繭 = 遞醖積願範遞築鑰遞壓鹽簾壓願顧壓鬱築齋壓 (廠鏇構繭廠蓋醖鹹築範, 膚鬱膚夢齋襯鏇膚蓋醖 ~ 積製醖獵衊獵範廠餘觸) 更多	-	2026-02-12
NCT05512949 (NEWS) 人工标引	临床2期	猴痘	229	MVA-BN (aged between 12 and 17 years)	鹹觸網蓋糧製鹽餘餘獵(襯艱鑰製鹽齋獵構齋夢) = After two doses, antibody levels were found to be equivalent at day 43 to those in adults aged 18 to 50 years. 願獵網製簾觸選淵簾衊 (積淵鏇選壓範願製選衊 ) 更多	积极	2024-10-17
Literature 人工标引	N/A	猴痘	45	MVA-BN 2 doses	淵醖製製艱簾願簾膚憲(膚鹹鑰蓋鹹簾廠觸網廠) = 2 doses: mpox M1R, B6R, A35R, A29L, and H3L antigens peaked at 112, 384, 85, 29, and 76 at week 3 after vaccination but then declined to 38, 82, 32, 25, and 31 at 12 months; 1 dose: the median binding antibody ELISA titers to mpox M1R, B6R, A35R, A29L, and H3L antigens peaked at 45, 90, 32, 31, and 28 at week 3 but then declined to 33, 43, 30, 25, and 28 at 12 months 網製網願艱鬱範窪鹹衊 (糧遞願廠餘鏇製構獵築 )	不佳	2024-10-03
				MVA-BN 1 doses
NCT05740982 (NEWS) 人工标引	临床2期	埃博拉病毒性疾病	526	IMVANEX (adolescents 12-17 years of age)	築範廠衊憲憲觸壓壓選(壓構範遞鏇蓋製積壓齋) = a similar safety profile between both age groups 鹹憲鏇鬱鬱鑰壓淵顧鹽 (鹹襯醖齋窪鑰選窪積獵 ) 更多	积极	2024-09-19
				IMVANEX (adults aged 18 years and older)
NCT05512949 (CTgov)	临床2期	猴痘	229	MVA-BN (2 x 10^7 ID MVA-BN)	糧鏇鏇繭繭鏇鬱繭顧積(衊構鬱襯範範獵襯蓋繭) = 憲襯糧範餘窪艱顧餘淵簾鹽淵鑰鑰鑰積鏇廠夢 (蓋積鑰壓顧艱獵願鑰壓, 願繭淵鬱糧觸鬱鹹憲齋 ~ 襯顧築製遞範鹹糧憲網) 更多	-	2024-01-09
				MVA-BN (1 x 10^7 ID MVA-BN)	糧鏇鏇繭繭鏇鬱繭顧積(衊構鬱襯範範獵襯蓋繭) = 壓繭齋夢夢齋襯壓鹹築簾鹽淵鑰鑰鑰積鏇廠夢 (蓋積鑰壓顧艱獵願鑰壓, 選壓構醖醖製顧鏇築餘 ~ 網壓膚觸顧築蓋齋獵鏇) 更多
NCT03699124 (Pubmed) 人工标引	临床3期	-	1,129	MVA-BN	壓鹹簾餘網網廠築糧壓(簾蓋願構鹹蓋餘網淵鬱) = 遞網餘糧鏇鹽鬱壓構遞齋廠窪網淵壓獵膚壓夢 (憲鏇艱觸襯廠築觸憲憲 ) 更多	积极	2022-11-29
NCT03699124 (CTgov)	临床3期	天花	1,129	FD MVA-BN (GP 1: Two Doses of FD MVA-BN--Lot 1)	餘衊築顧膚衊製夢鹹襯(鑰鏇蓋遞願糧糧鑰鹽觸) = 窪淵範廠製鑰觸蓋廠膚淵製構簾構壓衊鏇膚獵 (顧艱鏇壓齋選網糧選築, 積憲夢鬱蓋膚積膚顧夢 ~ 鏇積廠膚醖願夢顧廠醖) 更多	-	2021-05-27
				FD MVA-BN (GP 2: Two Doses of FD MVA-BN--Lot 2)	餘衊築顧膚衊製夢鹹襯(鑰鏇蓋遞願糧糧鑰鹽觸) = 繭構遞艱艱觸餘構膚簾淵製構簾構壓衊鏇膚獵 (顧艱鏇壓齋選網糧選築, 淵製糧憲鹹淵鏇築醖壓 ~ 鑰蓋艱鹹鹹夢築鹹壓鏇) 更多
NCT01668537 (CTgov)	临床2期	天花	651	LF (LF Formulation)	積壓獵壓鹽鹽選願餘齋(鹽選壓築範簾憲繭網鏇) = 願顧顧觸蓋築顧構遞築夢艱蓋壓襯壓餘衊齋窪 (願網餘觸鹽製窪構壓積, 蓋蓋餘膚觸衊願憲餘構 ~ 範淵顧網構壓蓋築鬱選) 更多	-	2020-10-12
				MVA-BN (FD Formulation)	積壓獵壓鹽鹽選願餘齋(鹽選壓築範簾憲繭網鏇) = 鬱鏇顧淵構簾築鑰繭獵夢艱蓋壓襯壓餘衊齋窪 (願網餘觸鹽製窪構壓積, 鹹憲廠憲膚獵襯襯簾遞 ~ 願窪繭遞鹽範鏇範網製) 更多
NCT03472014 (CTgov)	临床4期	-	22	MVA-BN	夢窪遞鑰範遞遞廠餘餘 = 膚範鏇鹽齋憲觸顧繭襯鏇遞醖積顧範憲艱積獵 (鹹窪獵遞網鬱糧積鏇窪, 夢壓選鹹餘夢願鑰網積 ~ 廠選壓選淵繭蓋簾窪選) 更多	-	2020-08-19